

Carsten Riether

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1202986/publications.pdf>

Version: 2024-02-01

67
papers

2,878
citations

172457

29
h-index

182427

51
g-index

68
all docs

68
docs citations

68
times ranked

5051
citing authors

#	ARTICLE	IF	CITATIONS
1	The CD70-CD27 axis in oncology: the new kids on the block. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 12.	8.6	53
2	Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre- and post-treatment biopsies in the multi-center SAKK19/09 study. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 405-415.	4.2	8
3	Metoclopramide treatment blocks CD93-signaling-mediated self-renewal of chronic myeloid leukemia stem cells. <i>Cell Reports</i> , 2021, 34, 108663.	6.4	21
4	ATG5 promotes eosinopoiesis but inhibits eosinophil effector functions. <i>Blood</i> , 2021, 137, 2958-2969.	1.4	11
5	LIGHT/LT β R signaling regulates self-renewal and differentiation of hematopoietic and leukemia stem cells. <i>Nature Communications</i> , 2021, 12, 1065.	12.8	9
6	Abstract PO-039: Radiation therapy enhances anti-tumor activity of a MET CAR T-based immunotherapy approach for glioblastoma multiforme. , 2021, , .		0
7	Electrospray Mediated Localized and Targeted Chemotherapy in a Mouse Model of Lung Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 643492.	3.5	3
8	Epigenetic Silencing of Immune-Checkpoint Receptors in Bone Marrow- Infiltrating T Cells in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 663406.	2.8	14
9	Tnfrsf4-expressing regulatory T cells promote immune escape of chronic myeloid leukemia stem cells. <i>JCI Insight</i> , 2021, 6, .	5.0	15
10	Avidity-Engineered CD3 Engaging DARPIn $\hat{\text{A}}^{\text{®}}$ Targeting Three Tumor Associated Antigens Induce Strong and Specific T Cell Dependent Killing of AML Cells with Potential for Improved Safety. <i>Blood</i> , 2021, 138, 1164-1164.	1.4	0
11	ATG12 deficiency leads to tumor cell oncosis owing to diminished mitochondrial biogenesis and reduced cellular bioenergetics. <i>Cell Death and Differentiation</i> , 2020, 27, 1965-1980.	11.2	20
12	BIF-1 inhibits both mitochondrial and glycolytic ATP production: its downregulation promotes melanoma growth. <i>Oncogene</i> , 2020, 39, 4944-4955.	5.9	5
13	Genetic Alterations Impact Immune Microenvironment Interactions in Follicular Lymphoma. <i>Cancer Cell</i> , 2020, 37, 621-622.	16.8	4
14	Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. <i>Nature Medicine</i> , 2020, 26, 1459-1467.	30.7	122
15	Eosinophils regulate adipose tissue inflammation and sustain physical and immunological fitness in old age. <i>Nature Metabolism</i> , 2020, 2, 688-702.	11.9	64
16	TNIK signaling imprints CD8+ T cell memory formation early after priming. <i>Nature Communications</i> , 2020, 11, 1632.	12.8	16
17	Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine. <i>Frontiers in Immunology</i> , 2019, 10, 1015.	4.8	39
18	Vaccination with nanoparticles combined with micro-adjuvants protects against cancer. , 2019, 7, 114.		41

#	ARTICLE	IF	CITATIONS
19	CD8+ T cells expand stem and progenitor cells in favorable but not adverse risk acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 2379-2392.	7.2	29
20	CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML. <i>Blood Advances</i> , 2019, 3, 3674-3687.	5.2	40
21	mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer. <i>Oncogene</i> , 2019, 38, 622-636.	5.9	37
22	Tumor Initiation Capacity and Therapy Resistance Are Differential Features of EMT-Related Subpopulations in the NSCLC Cell Line A549. <i>Neoplasia</i> , 2019, 21, 185-196.	5.3	38
23	T-cellâ€“Secreted TNFÎ± Induces Emergency Myelopoiesis and Myeloid-Derived Suppressor Cell Differentiation in Cancer. <i>Cancer Research</i> , 2019, 79, 346-359.	0.9	45
24	The Combination of the BCL-2 Antagonist Venetoclax with the CD70-Targeting Antibody Cusatuzumab Synergistically Eliminates Primary Human Leukemia Stem Cells. <i>Blood</i> , 2019, 134, 3918-3918.	1.4	6
25	Targeting CD70 with Cusatuzumab Eliminates Acute Myeloid Leukemia Stem Cells in Humans. <i>Blood</i> , 2019, 134, 234-234.	1.4	8
26	Combined mTOR inhibition and chemotherapy as an effective strategy to treat KRAS-mutant lung cancer. <i>Zentralblatt Fur Chirurgie</i> , 2019, 144, .	0.3	0
27	CD93-Signaling Regulates Self-Renewal and Proliferation of Chronic Myeloid Leukemia Stem Cells in Mice and Humans and Might be a Promising Target for Treatment. <i>Blood</i> , 2019, 134, 187-187.	1.4	0
28	Splenic CD24 ^{low} Red Pulp Macrophages Provide an Alternate Niche for Chronic Myeloid Leukemia Stem Cells. <i>Blood</i> , 2019, 134, 1634-1634.	1.4	1
29	T cell inhibitory mechanisms in a model of aggressive Non-Hodgkin's Lymphoma. <i>Oncolmunology</i> , 2018, 7, e1365997.	4.6	2
30	Osteolytic cancer cells induce vascular/axon guidance processes in the bone/bone marrow stroma. <i>Oncotarget</i> , 2018, 9, 28877-28896.	1.8	9
31	Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma. <i>British Journal of Cancer</i> , 2018, 119, 65-75.	6.4	26
32	Argx-110 Targeting CD70, in Combination with Azacitidine, Shows Favorable Safety Profile and Promising Anti-Leukemia Activity in Newly Diagnosed AML Patients in an Ongoing Phase 1/2 Clinical Trial. <i>Blood</i> , 2018, 132, 2680-2680.	1.4	16
33	CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies. <i>Blood</i> , 2017, 130, 297-309.	1.4	37
34	The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34+ Stem/Progenitor Cells. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1497-1510.	4.1	11
35	CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2017, 214, 359-380.	8.5	125
36	MA 15.11 CCNE1, PTGS2, TGFA and WISP2 Predict Benefit from Bevacizumab and Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (SAKK19/09). <i>Journal of Thoracic Oncology</i> , 2017, 12, S1864-S1865.	1.1	1

#	ARTICLE	IF	CITATIONS
37	TREM-1 links dyslipidemia to inflammation and lipid deposition in atherosclerosis. <i>Nature Communications</i> , 2016, 7, 13151.	12.8	76
38	CD127+ innate lymphoid cells are dysregulated in treatment naive acute myeloid leukemia patients at diagnosis. <i>Haematologica</i> , 2015, 100, e257-e260.	3.5	69
39	Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling. <i>Science Translational Medicine</i> , 2015, 7, 298ra119.	12.4	71
40	Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells. <i>Leukemia</i> , 2015, 29, 1781-1785.	7.2	26
41	Regulation of hematopoietic and leukemic stem cells by the immune system. <i>Cell Death and Differentiation</i> , 2015, 22, 187-198.	11.2	195
42	IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms. <i>Journal of Clinical Investigation</i> , 2015, 125, 2579-2591.	8.2	80
43	TREM-1 Deficiency Can Attenuate Disease Severity without Affecting Pathogen Clearance. <i>PLoS Pathogens</i> , 2014, 10, e1003900.	4.7	116
44	Cytotoxic CD8+ T Cells Stimulate Hematopoietic Progenitors by Promoting Cytokine Release from Bone Marrow Mesenchymal Stromal Cells. <i>Cell Stem Cell</i> , 2014, 14, 460-472.	11.1	174
45	CD70/CD27 Signaling Mediates Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors By Compensatory Activation of the Wnt Pathway. <i>Blood</i> , 2014, 124, 400-400.	1.4	1
46	Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon- γ . <i>Journal of Experimental Medicine</i> , 2013, 210, 605-621.	8.5	72
47	Neurobehavioural activation during peripheral immunosuppression. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 137-149.	2.1	24
48	Dendritic Cell-Based Immunotherapy for Myeloid Leukemias. <i>Frontiers in Immunology</i> , 2013, 4, 496.	4.8	37
49	Interferons in hematopoiesis and leukemia. <i>Oncolmmunology</i> , 2013, 2, e24572.	4.6	6
50	From "magic bullets" to specific cancer immunotherapy. <i>Swiss Medical Weekly</i> , 2013, 143, w13734.	1.6	10
51	Modulating CD27 signaling to treat cancer. <i>Oncolmmunology</i> , 2012, 1, 1604-1606.	4.6	24
52	CD27 Signaling Increases the Frequency of Regulatory T Cells and Promotes Tumor Growth. <i>Cancer Research</i> , 2012, 72, 3664-3676.	0.9	133
53	Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. <i>Journal of Neuroinflammation</i> , 2012, 9, 151.	7.2	314
54	Victims of rape show increased cortisol responses to trauma reminders: A study in individuals with war- and torture-related PTSD. <i>Psychoneuroendocrinology</i> , 2012, 37, 213-220.	2.7	50

#	ARTICLE	IF	CITATIONS
55	CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression. <i>Journal of Clinical Investigation</i> , 2012, 122, 624-638.	8.2	84
56	Electrical activity in rat cortico-limbic structures after single or repeated administration of lipopolysaccharide or staphylococcal enterotoxin B. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2011, 278, 1864-1872.	2.6	25
57	Stimulation of β 2-adrenergic receptors inhibits calcineurin activity in CD4+ T cells via PKA \leftrightarrow AKAP interaction. <i>Brain, Behavior, and Immunity</i> , 2011, 25, 59-66.	4.1	55
58	Attenuation of the cytotoxic T lymphocyte response to lymphocytic choriomeningitis virus in mice subjected to chronic social stress. <i>Brain, Behavior, and Immunity</i> , 2011, 25, 340-348.	4.1	15
59	Acute amygdaloid response to systemic inflammation. <i>Brain, Behavior, and Immunity</i> , 2011, 25, 1384-1392.	4.1	88
60	Chemical destruction of brain noradrenergic neurons affects splenic cytokine production. <i>Journal of Neuroimmunology</i> , 2010, 219, 75-80.	2.3	16
61	Calcineurin inhibition in splenocytes induced by pavlovian conditioning. <i>FASEB Journal</i> , 2009, 23, 1161-1167.	0.5	41
62	No PTSD-related differences in diurnal cortisol profiles of genocide survivors. <i>Psychoneuroendocrinology</i> , 2009, 34, 523-531.	2.7	28
63	Time-dependent alterations of peripheral immune parameters after nigrostriatal dopamine depletion in a rat model of Parkinson's disease. <i>Brain, Behavior, and Immunity</i> , 2009, 23, 518-526.	4.1	56
64	No Retrieval-Induced Forgetting Under Stress. <i>Psychological Science</i> , 2009, 20, 1356-1363.	3.3	56
65	Weaken taste-LPS association during endotoxin tolerance. <i>Physiology and Behavior</i> , 2008, 93, 261-266.	2.1	15
66	Behavioural Conditioning of Immune Functions: How the Central Nervous System Controls Peripheral Immune Responses by Evoking Associative Learning Processes. <i>Reviews in the Neurosciences</i> , 2008, 19, 1-18.	2.9	34
67	Neuro-Immune Associative Learning. , 2008, , 123-150.		0